Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond.
about
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor MicroenvironmentGuidelines for the welfare and use of animals in cancer research.Intensity of the vaccine-elicited immune response determines tumor clearance.Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells
P2860
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Monitoring specific T-cell res ...... LISPOT, tetramers, and beyond.
@en
Monitoring specific T-cell res ...... LISPOT, tetramers, and beyond.
@nl
type
label
Monitoring specific T-cell res ...... LISPOT, tetramers, and beyond.
@en
Monitoring specific T-cell res ...... LISPOT, tetramers, and beyond.
@nl
prefLabel
Monitoring specific T-cell res ...... LISPOT, tetramers, and beyond.
@en
Monitoring specific T-cell res ...... LISPOT, tetramers, and beyond.
@nl
P2860
P1476
Monitoring specific T-cell res ...... LISPOT, tetramers, and beyond.
@en
P2093
T F Gajewski
P2860
P304
P356
10.1128/CDLI.7.2.141-144.2000
P577
2000-03-01T00:00:00Z